Compare Adaptive Biotechnologies Corp (ADPT) vs Warner Music Group Corp (WMG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Warner Music Group Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Warner Music Group Corp trades at $28.51 (market cap $14.83B). The key difference: Warner Music Group Corp is far larger — about 4.5× Adaptive Biotechnologies Corp's market cap, and Warner Music Group Corp pays a 2.67% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WMG | |
|---|---|---|
Market Cap | $3.33B | $14.83B |
Sector | Health | Media |
52-Week High | $22.37 | $34.72 |
52-Week Low | $10.24 | $23.65 |
Enterprise Value | $3.19B | $19.03B |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Warner Music Group (WMG) trades at $28.44, up 0.57% today, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $0.35, beating expectations, and announced the acquisition of Sureel AI to strengthen IP management. Financials show revenue growth to $6.71B in 2025, though net income margin declined to 5.44%. Valuation ratios include a P/E of 32.62 and P/S of 2.01, with a consensus analyst price target of $40.40 indicating significant upside potential.
WMG presents a mixed outlook: strong analyst support (66.7% buy ratings) and strategic AI investments offer growth opportunities, but bearish technicals, declining net margins, and competitive pressures pose risks. The stock's current price near support at $27 suggests cautious investor sentiment, with earnings consistency and margin improvement key to unlocking upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
